If you notice text formatting issues, please update your browser to view the website correctly
.
See More
If you notice text formatting issues, please update your browser to view the website correctly
.
See MoreIf you notice text formatting issues, please update your browser to view the website correctly
.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Ly-6G expression on mouse bone-marrow leucocytes. Mouse bone-marrow cells were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were stained with either BD Horizon™ BB700 Rat IgG2a, κ Isotype Control (Cat. No. 566413; dashed line histogram) or BD Horizon BB700 Rat Anti-Mouse LY-6G antibody (Cat. No. 566435/566453; solid line histogram) at 0.5 μg/ml. Cells were then stained with BD Via-Probe™ Red Nucleic Acid Stain (Cat. No. 565803/565804) and analyzed. The fluorescence histograms showing Ly-6G fluorescence (or Ig Isotype control staining) were derived from gated events with the light scattering characteristics of viable lymphoid (Left Panel) or myeloid (Right Panel) cells that were Via Probe Red-negative. Flow cytometric analysis was performed using a BD LSRFortessa™ X-20 Cell Analyzer System. Data shown on this Technical Data Sheet are not lot specific.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794 or 566349).
When setting up compensation, it is recommended to compare spillover values obtained from cells and BD™ CompBeads to ensure that beads will provide sufficiently accurate spillover values.
For optimal results, it is recommended to perform two washes after staining with antibodies. Cells may be prepared, stained with antibodies and washed twice with wash buffer per established protocols for immunofluorescent staining, prior to acquisition on a flow cytometer. Performing fewer than the recommended wash steps may lead to increased spread of the negative population.
The 1A8 monoclonal antibody specifically binds to Ly-6G, a 21-25-kDa GPI-anchored protein. In the bone marrow, Ly6G is expressed on the majority of the largest cells, predominantly granulocytes, but not on lymphoid or erythroid cells. In the periphery, it is expressed on granulocytes. The mAb RB6-8C5 recognizes both Ly-6G and Ly-6C and blocks the binding of mAb 1A8 to Ly-6G.
The antibody was conjugated to BD Horizon BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes. It is a polymer-based tandem dye developed exclusively by BD Biosciences. With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.